NervGen Pharma Approved for Nasdaq Listing, Advancing SCI Treatment Drug Development

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Jan 08 2026

0mins

NGEN+2.06%

Should l Buy NGEN?

Source: NASDAQ.COM

Nasdaq Listing: NervGen Pharma's common shares have been approved for listing on Nasdaq under the symbol "NGEN", marking a transition from the U.S. OTC market to a more liquid trading platform, which is expected to attract greater investor interest.
Drug Development Progress: The company's lead drug, NVG-291, is in Phase 2 clinical trials, having received Fast Track designation from the FDA in October 2023, indicating its potential as the first pharmacologic therapy for spinal cord injury (SCI).
Clinical Study Results: In the CONNECT SCI study announced on November 24, 2025, NVG-291 demonstrated significant improvements in function, independence, and quality of life for chronic SCI patients, further enhancing its market prospects.
Future Plans: NervGen plans to hold an End-of-Phase 2 meeting with the FDA in early 2026 to align on the development and registration pathway for NVG-291, demonstrating the company's strong commitment to advancing SCI treatment.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NGEN?" and start using high-conviction signals backed by rigorous historical data.

NGEN

$3.96+Infinity%1D

Analyst Views on NGEN

About NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

NervGen Pharma Appoints New CEO Adam Rogers

8 hours agoseekingalpha

New CEO Appointment: NervGen Pharma has unanimously appointed Dr. Adam Rogers as the new president and CEO, effective immediately, following his successful tenure as interim CEO where he achieved key milestones.
Successful Nasdaq Listing: Under Rogers' leadership, the company successfully listed on Nasdaq, marking a significant advancement in its capital market presence and laying the groundwork for future financing and business expansion.
Product Development Progress: NervGen's lead candidate NVG-291 has advanced to late-stage development, potentially paving the way for commercialization and enhancing the company's competitive position in the market.
Funding Initiative Launched: NervGen Pharma announced a $10 million non-brokered private placement aimed at providing funding for subsequent R&D and market promotion, reflecting the company's confidence in future growth.